Marc Cohen (NextRNA Therapeutics)

C4 co-founder re­signs as Dana-Far­ber trustee in the wake of new con­flict of in­ter­est poli­cies — re­port

Two long­time trustees of Dana-Far­ber Can­cer In­sti­tute have re­signed in the wake of an in­ves­ti­ga­tion by the Boston Globe’s Spot­light team in­to its some­what un­ortho­dox prac­tice of al­low­ing trustees to in­vest in its biotech spin­outs and even — at one time — ne­go­ti­ate on be­half of those star­tups.

Marc Co­hen, a se­r­i­al biotech en­tre­pre­neur and in­vestor who co-found­ed the pro­tein degra­da­tion pi­o­neer C4 Ther­a­peu­tics with Jay Brad­ner, and re­tired Har­vard Busi­ness School pro­fes­sor Mal­colm Salter said they will now fo­cus on ad­vis­ing the in­sti­tute’s ven­ture phil­an­thropy pro­gram, launched last year. They joined the board in 2004 and 1998, re­spec­tive­ly, be­fore re­sign­ing last week.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.